HUE051648T2 - CCR3-gátlók használata - Google Patents

CCR3-gátlók használata

Info

Publication number
HUE051648T2
HUE051648T2 HUE13713199A HUE13713199A HUE051648T2 HU E051648 T2 HUE051648 T2 HU E051648T2 HU E13713199 A HUE13713199 A HU E13713199A HU E13713199 A HUE13713199 A HU E13713199A HU E051648 T2 HUE051648 T2 HU E051648T2
Authority
HU
Hungary
Prior art keywords
ccr3 inhibitors
ccr3
inhibitors
Prior art date
Application number
HUE13713199A
Other languages
English (en)
Hungarian (hu)
Inventor
Michael Chadham Nivens
Thierry Bouyssou
Rolf Goeggel
Peter Seither
Original Assignee
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48040249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE051648(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkahest Inc filed Critical Alkahest Inc
Publication of HUE051648T2 publication Critical patent/HUE051648T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Structure Of Transmissions (AREA)
HUE13713199A 2012-04-03 2013-04-02 CCR3-gátlók használata HUE051648T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12162937 2012-04-03

Publications (1)

Publication Number Publication Date
HUE051648T2 true HUE051648T2 (hu) 2021-03-29

Family

ID=48040249

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13713199A HUE051648T2 (hu) 2012-04-03 2013-04-02 CCR3-gátlók használata

Country Status (28)

Country Link
US (5) US20130261153A1 (enExample)
EP (3) EP2833884B1 (enExample)
JP (2) JP2015512432A (enExample)
KR (5) KR20220132012A (enExample)
CN (2) CN104220073A (enExample)
AU (1) AU2013245027B2 (enExample)
BR (1) BR112014023795B1 (enExample)
CA (1) CA2869269C (enExample)
CL (1) CL2014002523A1 (enExample)
CY (1) CY1123222T1 (enExample)
DK (1) DK2833884T3 (enExample)
EA (1) EA032263B1 (enExample)
ES (2) ES2987267T3 (enExample)
HR (1) HRP20201165T1 (enExample)
HU (1) HUE051648T2 (enExample)
IL (1) IL234262A (enExample)
IN (1) IN2014DN06989A (enExample)
LT (1) LT2833884T (enExample)
MX (1) MX2014011786A (enExample)
NZ (1) NZ628882A (enExample)
PH (1) PH12014502239A1 (enExample)
PL (1) PL2833884T3 (enExample)
PT (1) PT2833884T (enExample)
RS (1) RS60665B1 (enExample)
SI (1) SI2833884T1 (enExample)
SM (1) SMT202000499T1 (enExample)
WO (1) WO2013149986A1 (enExample)
ZA (1) ZA201406082B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
WO2018097209A1 (ja) 2016-11-24 2018-05-31 キリシマ精工株式会社 歯列矯正具、および歯列矯正具の取付方法
US11382907B2 (en) * 2017-04-05 2022-07-12 Alkahest, Inc. Methods and compositions for treating aging-associated impairments using CCR3-inhibitors
SG11201909207VA (en) * 2017-04-05 2019-11-28 Alkahest Inc Methods and compositions for treating retina-associated disease using ccr3-inhibitors
WO2019075351A1 (en) * 2017-10-13 2019-04-18 Alkahest, Inc. METHODS AND COMPOSITIONS FOR TREATING PRURIT, XEROSIS AND ASSOCIATED DISEASE USING CCR3 INHIBITORS
MY198220A (en) 2018-05-15 2023-08-14 Alkahest Inc Treatment Of Aging-Associated Disease With Modulators Of Leukotriene A4 Hydrolase
AU2019346456A1 (en) * 2018-09-26 2021-04-15 Alkahest, Inc. Methods and compositions for treating aging-associated impairments using CCR3-inhibitors
AU2021287906B2 (en) * 2020-06-11 2025-09-11 Alkahest Inc. Methods of improving retina-associated disease outcome using CCR3-inhibitors
WO2023076679A1 (en) 2021-11-01 2023-05-04 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339087B1 (en) * 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
JP5198704B2 (ja) * 2000-03-03 2013-05-15 メディミューン リミティド エオタキシンに対するヒト抗体及びそれらの使用
US20020151064A1 (en) * 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
US8030003B2 (en) * 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
US8008092B2 (en) * 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
WO2010069979A1 (en) * 2008-12-16 2010-06-24 Nycomed Gmbh Pyran derivatives as ccr3 modulators
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
US8778616B2 (en) * 2009-05-26 2014-07-15 University Of Kentucky Research Foundation Method of using CCR3 binding agents to detect choroidal neovascularization
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
WO2020115836A1 (ja) * 2018-12-05 2020-06-11 東浜工業株式会社 ブロワー装置

Also Published As

Publication number Publication date
CL2014002523A1 (es) 2015-01-23
NZ628882A (en) 2016-05-27
PT2833884T (pt) 2020-08-26
CA2869269A1 (en) 2013-10-10
IL234262A (en) 2017-10-31
EP4389217A3 (en) 2024-08-28
KR20250133980A (ko) 2025-09-09
US20160081998A1 (en) 2016-03-24
ZA201406082B (en) 2019-01-30
DK2833884T3 (da) 2020-08-10
BR112014023795B1 (pt) 2021-09-08
KR20140144200A (ko) 2014-12-18
AU2013245027B2 (en) 2017-10-12
US20150099783A1 (en) 2015-04-09
US20170319567A1 (en) 2017-11-09
ES2811554T3 (es) 2021-03-12
MX2014011786A (es) 2014-12-05
BR112014023795A8 (pt) 2017-10-10
CN110384699A (zh) 2019-10-29
CN104220073A (zh) 2014-12-17
KR20210063481A (ko) 2021-06-01
PH12014502239A1 (en) 2014-12-15
SI2833884T1 (sl) 2020-10-30
HRP20201165T1 (hr) 2020-12-11
EA201401083A1 (ru) 2015-03-31
AU2013245027A1 (en) 2014-09-11
WO2013149986A1 (en) 2013-10-10
KR20200044988A (ko) 2020-04-29
EP2833884B1 (en) 2020-05-20
EA032263B1 (ru) 2019-05-31
US20130261153A1 (en) 2013-10-03
JP2015512432A (ja) 2015-04-27
ES2987267T3 (es) 2024-11-14
EP3763369A1 (en) 2021-01-13
PL2833884T3 (pl) 2020-11-02
JP2018080183A (ja) 2018-05-24
EP2833884A1 (en) 2015-02-11
CY1123222T1 (el) 2021-10-29
IN2014DN06989A (enExample) 2015-04-10
SMT202000499T1 (it) 2020-11-10
BR112014023795A2 (enExample) 2017-06-20
EP3763369B1 (en) 2024-02-28
EP4389217A2 (en) 2024-06-26
KR20220132012A (ko) 2022-09-29
LT2833884T (lt) 2020-09-10
RS60665B1 (sr) 2020-09-30
US20200375971A1 (en) 2020-12-03
CA2869269C (en) 2020-06-30

Similar Documents

Publication Publication Date Title
SMT201700109B (it) Inibitori di istone demetilasi
LT2841428T (lt) Dnr-pk inhibitoriai
SMT201700052B (it) 2-(azaindol-2-il)benzimidazoli come inibitori di pad4
SMT201700094B (it) Composto di pirazina carbossammide
LT2895484T (lt) Gliukozilceramido sintazės inhibitoriai
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
SMT201600114B (it) Inibitori di beta-secretasi
HRP20182037T1 (hr) Inhibitori prmt5 i njihova uporaba
IL227764A0 (en) Pyrrolotriazinone derivatives as pi3k inhibitors
HUE051648T2 (hu) CCR3-gátlók használata
HUE036259T2 (hu) Inhibitor vegyületek
HRP20181786T1 (hr) Inhibitori aktivacije t-stanica
LT2885010T (lt) Tautopatijos gydymo būdai
HUE057264T2 (hu) Eljárás új IDH1 inhibitorok elõállítására
HUE040055T2 (hu) RET inhibitor
DK2920168T3 (da) Heterocykliske glutaminase-inhibitorer
DK2804858T3 (da) Metalloenzym-inhibitorforbindelser
PL2703054T3 (pl) Przyłączalny klocek
EP3632467C0 (en) COMPLEMENT FACTOR H INHIBITORS
EP2858975A4 (en) FBXO3 INHIBITORS
EP2629616A4 (en) SUBSTITUTED AMINO-TRIAZOLYL-PDE10-HEMMER
DK2888228T3 (da) Inhibitorer af CD40-TRAF6 interaktion
EP2882430A4 (en) ANTIBACTERIAL INHIBITORS
EP2755663A4 (en) MicroRNA Inhibitors
EP2691846A4 (en) USE OF METADATA